Rate of Carbapenemase Intestinal Carrier Inside ICUNCT07255443
Intestinal Colonization With Carbapenem Resistant Enterobacteriaceae Among ICU Patients at Assiut University Hospital
An observational study of Rate of Carbapenemase Intestinal Carrier Inside ICU, run by Israa Ahmed abdelhalim.
Trial summary
significant benefits by providing data to improve infection control, guide early detection, and reduce CRE transmission in ICUs. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rate of Carbapenemase Intestinal Carrier Inside ICU
- What is being tested?
- Observational study
- How many people
- 120 participants
- Where
- No sites listed yet
- Study dates
- 1 Feb 2026to 5 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All eligible adult patients admitted during the study period
Who may be able to join
- Adults (≥18 years)_
- Expected ICU stay ≥48 hours -
Who cannot join
- .ICU stay <48 hours
About this study
significant benefits by providing data to improve infection control, guide early detection, and reduce CRE transmission in ICUs.
- Being tested
- Observational study
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational studyOther
Observational study
| Study group | Role | What they receive |
|---|---|---|
| Prospective cohort study conducted in the Adult ICU at Assiut University Hospital | Not described Receives: Other: Observational study |
What is being measured
The primary outcome is the main question the study is designed to answer.
rate of intestinal colonization with CRE
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2025
- Study start1 Feb 2026 (estimated)
- Primary completion1 Feb 2027 (estimated)
- Study completion5 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rate of Carbapenemase Intestinal Carrier Inside ICUStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Israa Ahmed abdelhalim
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Israa Ahmed abdelhalim, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07255443
- Sponsor's protocol ID
- Assiut_icu_catbapenem_2025
- Status last verified
- Nov 2025
- First submitted
- 20 Nov 2025
- Last updated
- 1 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intestinal Colonization With Carbapenem Resistant Enterobacteriaceae Among ICU Patients at Assiut University Hospital
- ClinicalTrials.gov ID
- NCT07255443
- Acronym / sponsor ID
- Assiut_icu_catbapenem_2025
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Israa Ahmed abdelhalimUniversity, hospital or other
- Study start
- 1 Feb 2026 (estimated)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 5 Jun 2027 (estimated)
- First posted
- 1 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
significant benefits by providing data to improve infection control, guide early detection, and reduce CRE transmission in ICUs.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Prospective cohort study conducted in the Adult ICU at Assiut University Hospital | – | Other: Observational study |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All eligible adult patients admitted during the study period
Key inclusion criteria (2 listed)
- Adults (≥18 years)_
Key exclusion criteria (1 listed)
- .ICU stay <48 hours
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational studyObservational study | Other | Prospective cohort study conducted in the Adult ICU at Assiut University Hospital |
Primary outcome
rate of intestinal colonization with CRE
Time frame: One year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Dec 2025.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Rate of Carbapenemase Intestinal Carrier Inside ICU, run by Israa Ahmed abdelhalim.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
rate of intestinal colonization with CRE (time frame: One year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2025.